Takhzyro

Active Ingredient(s): Lanadelumab (shp643)
FDA Approved: * August 23, 2018
Pharm Company: * DYAX CORP.

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Takhzyro Overview

Lanadelumab (INN) (alternative identifier DX-2930[1]) is a human monoclonal antibody (class IgG1 kappa)[2] that targets plasma kallikrein (pKal)[1] in order to promote prevention of angioedema in patients with hereditary angioedema.[3][4] In phase 1 clinical trials Lanadelumab was well tolerated and was reported to reduce cleavage of kininogen in the plasma of patients with hereditary angioedeman and decrease the ...

Read more Takhzyro Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Lanadelumab

Recent Takhzyro Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Lanadelumab (shp643)
  • Injection: 300mg/ml(150mg/ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Takhzyro: (1 result)

Sorted by National Drug Code
  • 47783-644 Takhzyro 300 mg/2ml Subcutaneous Injection, Solution by Dyax Corp.

Other drugs which contain Lanadelumab (shp643) or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 15 October 2018.

We are committed to your privacy.

Copyright © 2005-2018 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 501 S. Cherry St, Suite 1100, Denver, CO, 80246, USA